ITEM 5.02DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On April 25, 2022, the board of directors of Cell MedX Corp. (the "Company")
unanimously resolved to increase the number of directors of the Company to six
directors and to appoint Mr. Dwayne Yaretz as a director to fill the vacancy
created by the increase in the number of directors. In addition, Mr. Yaretz was
appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who
resigned from his position as CEO of the Company on April 25, 2022. Mr. McEnulty
will continue to serve on the Company's board of directors.
Mr. Yaretz' experience spans many industries including the development of
industrial and medical imaging devices. He has aided in the re-structure of
numerous companies by identifying and recruiting key personnel, enhancing the
management team, capitalization, and maximizing business and sales
opportunities. In the past, Mr. Yaretz has acted as a director, and held various
top management positions, including CEO, CFO and president, with both private
and public companies.
There is no family relationship among the directors. There are currently no
compensation arrangements with Mr. Yaretz for acting as a member of the board of
directors, or as the CEO.
A copy of the Company's news release regarding the appointment of Mr. Yaretz and
resignation of Mr. McEnulty is attached as Exhibit 99.1 hereto.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
The following exhibits are provided with this Current Report:
Exhibit
Number Description of Exhibit
99.1 News Release dated April 27, 2022.
--------------------------------------------------------------------------------
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CELL MEDX CORP. 
